James Huang - 18 Mar 2026 Form 3 Insider Report for CASI Pharmaceuticals, Inc. (CASIF)

Role
Director
Signature
/s/ James Huang
Issuer symbol
CASIF
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 16:30:37 UTC
Previous filing
08 Jun 2023
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Huang James Director C/O PANACEA VENTURE, NO. 5, LANE 1350, FUXING MIDDLE ROAD, SHANGHAI, CHINA /s/ James Huang 18 Mar 2026 0001573160

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CASIF Ordinary Shares 4,529,956 18 Mar 2026 See Footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CASIF Stock Option 18 Mar 2026 Ordinary Shares 10,000 $1.69 Direct F2
holding CASIF Stock Option 18 Mar 2026 Ordinary Shares 10,000 $2.69 Direct F2
holding CASIF Stock Option 18 Mar 2026 Ordinary Shares 101,571 $1.93 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Panacea Venture Healthcare Fund II, L.P. is the record holder of the Ordinary Shares reported herein. James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd., which is the general partner of Panacea Venture Healthcare Fund II, L.P. As a result, James Huang may be deemed to share beneficial ownership of the Ordinary Shares reported herein, but disclaims such beneficial ownership.
F2 The stock option is fully vested and exercisable.